Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

BACKGROUND In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemok...

Descripción completa

Detalles Bibliográficos
Autores: Novillo Villajos, Apolonia, Gaibar Alonso, María, Romero Lorca, Alicia, Fuencisla Gilsanz, María, Beltrán, Laura, Galán Burgos, Miguel, Antón, Beatriz, Malón, Diego, Moreno, Amalia, Fernández Santander, Ana
Tipo de recurso: artículo
Fecha de publicación:2020
País:España
Institución:Universidad Europea (UEM)
Repositorio:ABACUS. Repositorio de Producción Científica
Idioma:inglés
OAI Identifier:oai:abacus.universidadeuropea.com:11268/9259
Acceso en línea:http://hdl.handle.net/11268/9259
Access Level:acceso abierto
Palabra clave:Quimioterapia
Terapéutica
Cáncer
Tratamiento médico
id ES_e2ebd5a628d29af950bdcd2d16238a89
oai_identifier_str oai:abacus.universidadeuropea.com:11268/9259
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reportsNovillo Villajos, ApoloniaGaibar Alonso, MaríaRomero Lorca, AliciaFuencisla Gilsanz, MaríaBeltrán, LauraGalán Burgos, MiguelAntón, BeatrizMalón, DiegoMoreno, AmaliaFernández Santander, AnaQuimioterapiaTerapéuticaCáncerTratamiento médicoBACKGROUND In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker, few studies have examined its relationship with drug efficacy. This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment. CASE SUMMARY We report six cases of stage IV KRAS-mutated mCRC. Patients were given first line treatment with BVZ-containing chemotherapy in University Hospital of Fuenlabrada. The six patients differed in terms of primary tumor location (right/left side), tumor burden (mostly hepatic and peritoneal disease) and clinical disease course. Before treatment onset, total RNA was isolated from paraffinated tumor biopsy specimens and CXCL5 gene expression quantified through conventional RT-qPCR procedures. Our main finding was that CXCL5 expression levels were several times higher in three patients with lower progression free survival (under 6 mo) from the start of treatment. CONCLUSION A higher expression of CXCL5 was observed in the three patients showing worse tumor response to treatment.20202020-10-3020202020-01-0120202020-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/11268/9259reponame:ABACUS. Repositorio de Producción Científicainstname:Universidad Europea (UEM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:abacus.universidadeuropea.com:11268/92592026-06-11T12:41:27Z
dc.title.none.fl_str_mv Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
title Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
spellingShingle Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
Novillo Villajos, Apolonia
Quimioterapia
Terapéutica
Cáncer
Tratamiento médico
title_short Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
title_full Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
title_fullStr Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
title_full_unstemmed Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
title_sort Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
dc.creator.none.fl_str_mv Novillo Villajos, Apolonia
Gaibar Alonso, María
Romero Lorca, Alicia
Fuencisla Gilsanz, María
Beltrán, Laura
Galán Burgos, Miguel
Antón, Beatriz
Malón, Diego
Moreno, Amalia
Fernández Santander, Ana
author Novillo Villajos, Apolonia
author_facet Novillo Villajos, Apolonia
Gaibar Alonso, María
Romero Lorca, Alicia
Fuencisla Gilsanz, María
Beltrán, Laura
Galán Burgos, Miguel
Antón, Beatriz
Malón, Diego
Moreno, Amalia
Fernández Santander, Ana
author_role author
author2 Gaibar Alonso, María
Romero Lorca, Alicia
Fuencisla Gilsanz, María
Beltrán, Laura
Galán Burgos, Miguel
Antón, Beatriz
Malón, Diego
Moreno, Amalia
Fernández Santander, Ana
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Quimioterapia
Terapéutica
Cáncer
Tratamiento médico
topic Quimioterapia
Terapéutica
Cáncer
Tratamiento médico
description BACKGROUND In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves progression-free survival compared to chemotherapy (CT) alone. This benefit is not, however, observed in all patients. While increased chemokine CXCL5 gene expression promoting angiogenesis has been proposed as a prognostic mCRC biomarker, few studies have examined its relationship with drug efficacy. This study sought to analyze tumor CXCL5 gene expression in six patients with different efficacy of BVZ-containing CT in terms of the tumor response to treatment. CASE SUMMARY We report six cases of stage IV KRAS-mutated mCRC. Patients were given first line treatment with BVZ-containing chemotherapy in University Hospital of Fuenlabrada. The six patients differed in terms of primary tumor location (right/left side), tumor burden (mostly hepatic and peritoneal disease) and clinical disease course. Before treatment onset, total RNA was isolated from paraffinated tumor biopsy specimens and CXCL5 gene expression quantified through conventional RT-qPCR procedures. Our main finding was that CXCL5 expression levels were several times higher in three patients with lower progression free survival (under 6 mo) from the start of treatment. CONCLUSION A higher expression of CXCL5 was observed in the three patients showing worse tumor response to treatment.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-10-30
2020
2020-01-01
2020
2020-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/11268/9259
url http://hdl.handle.net/11268/9259
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:ABACUS. Repositorio de Producción Científica
instname:Universidad Europea (UEM)
instname_str Universidad Europea (UEM)
reponame_str ABACUS. Repositorio de Producción Científica
collection ABACUS. Repositorio de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422454699458560
score 15,300724

Similares en LA Referencia